Abstract:Cervical cancer is a major cause of death in women despite the advancement of current treatment modalities. The conventional therapeutic agent, cisplatin (CCDP), is the standard treatment for CC; however, resistance often develops due to the cancer's heterogeneity. Therefore, a detailed elucidation of the specific molecular mechanisms driving CC is crucial for the development of targeted therapeutic strategies. Retinoblastoma binding protein 6 (RBBP6) is a potential biomarker associated with cell proliferation and is upregulated in cervical cancer sites, exhibiting apoptosis and dysregulated p53 expression. Furthermore, RBBP6 has been demonstrated to sensitize cancer cells to radiation and certain chemotherapeutic agents by regulating the Bcl-2 gene, thus suggesting a crosstalk among RBBP6/p53/BCL-2 oncogenic signatures. The present study, therefore, investigated the relationship between cisplatin and RBBP6 expression in CC cells. Herein, we first explored bioinformatics simulations and identified that the RBBP6/p53/BCL-2 signaling pathway is overexpressed and correlated with CC. For further analysis, we explored the Genomics of Drug Sensitivity in Cancer (GDSC) and found that most of the CC cell lines are sensitive to CCDP. To validate these findings, RBBP6 was silenced in HeLa and Vero cells using RNAi technology, followed by measurement of wild-type p53 and Bcl-2 at the mRNA level using qPCR. Cells co-treated with cisplatin and siRBBP6 were subsequently analyzed for apoptosis induction and real-time growth monitoring using flow cytometry and the xCELLigence system, respectively. Cancer cells in the co-treatment group showed a reduction in apoptosis compared to the cisplatin-treated group. Moreover, the real-time growth monitoring revealed a reduced growth rate in RBBP6 knockdown cells treated with cisplatin. Although wild-type p53 remained unchanged in the co-treatment group of cancer cells, Bcl-2 was completely repressed, suggesting that RBBP6 is necessary for sensitizing cervical cancer cells to cisplatin treatment by downregulating Bcl-2. The Vero cell population, which served as a non-cancerous control cell line in this study, remained viable following treatment with both siRBBP6 and cisplatin. Findings from this study suggest that RBBP6 expression promotes cisplatin sensitivity in HeLa cells through Bcl-2 downregulation. Knockdown of RBBP6 limits apoptosis induction and delays cell growth inhibition in response to cisplatin. The knowledge obtained here has the potential to help improve cisplatin efficacy through personalized administration based on the expression profile of RBBP6 among individual patients.

Downregulation of RhoB Inhibits Cervical Cancer Progression and Enhances Cisplatin Sensitivity

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

RhoB Acts As a Tumor Suppressor That Inhibits Malignancy of Clear Cell Renal Cell Carcinoma

A distinct role of RhoB in gastric cancer suppression.

Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells

Knock-down of NDRG2 Sensitizes Cervical Cancer Hela Cells to Cisplatin Through Suppressing Bcl-2 Expression.

Effects and Mechanism of RhoC Downregulation in Suppressing Ovarian Cancer Stem Cell Proliferation, Drug Resistance, Invasion and Metastasis

Enhancement of Cisplatin-Induced Cytotoxicity Against Cervical Cancer Spheroid Cells by Targeting Long Non-Coding RNAs.

miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer

Downregulation of SOX21-AS1 Alleviated Cisplatin Resistance in Cervical Cancer Through Epithelial-Mesenchymal Transition Inhibition

Downregulation of LINC01857 Increases Sensitivity of Gastric Carcinoma Cells to Cisplatin

Pin1 Modulates Chemo-Resistance by Up-Regulating FoxM1 and the Involvements of Wnt/β-catenin Signaling Pathway in Cervical Cancer

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

Abstract 3762: Downregulation of TRPC3 Enhances Sensitivity to Cisplatin and Inhibits Motility in Epithelial Ovarian Cancer

Overexpression of RhoA promotes the proliferation and migration of cervical cancer cells.

The Mir-136-5p/rock1 Axis Suppresses Invasion and Migration, and Enhances Cisplatin Sensitivity in Head and Neck Cancer Cells.

The role of CTHRC1 in cisplatin-resistance of ovarian cancer cells and related mechanisms

Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3

MicroRNA-19a and Microrna-19B Promote the Malignancy of Clear Cell Renal Cell Carcinoma Through Targeting the Tumor Suppressor RhoB

RhoC in association with TET2/WDR5 regulates cancer stem cells by epigenetically modifying the expression of pluripotency genes